Drug Profile
MGB 453
Alternative Names: MGB453Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD223 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Cancer in USA (IV) (Novartis pipeline, August 2023)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 21 Oct 2015 Preclinical trials in Cancer in USA (IV) prior to October 2015